Latest Breaking News On - Meeting presentations - Page 1 : vimarsana.com

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual.

Kamy poolerGreg davisAmerican society of gene cell therapyDevelopment of bloodHead of research at sangamoDevelopment of modular integrases mintsHead of technology at sangamoSangamo therapeutics incFormulation developmentExchange commissionSangamo therapeuticsAmerican societyCell therapyModular integrasesDravet syndromeMeeting presentations

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

– Consistent safety and efficacy profiles across adult and pediatric populations –

United statesSharon klahreNeil gallagherAmerican society of hematology annual meetingSyndax pharmaceuticalsHead of researchExchange commissionEuropean commissionTime oncology review programPrnewswire syndax pharmaceuticalsAmerican society of pediatric hematology oncologySyndax pharmaceuticals incPlenary sessionAcute leukemiaMeeting presentationsAmerican society

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSharon klahreRevumenib monotherapyIbrahim aldossMichaela metzgerSyndax pharmaceuticalsOncology centerExchange commissionSyndax pharmaceuticals incPrnewswire syndax pharmaceuticals nasdaqEuropean commissionData monitoring committeeAmerican society of hematologyDrug administrationDivision of leukemia

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoIbrahim aldossSharon klahreRevumenib monotherapyMichaela metzgerDivision of leukemiaAmerican society of hematologyExchange commissionData monitoring committeeDrug administrationOncology centerEuropean commissionSyndax pharmaceuticals incSyndax pharmaceuticalsPrnewswire syndax pharmaceuticals nasdaq

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSharon klahreMichaela metzgerExchange commissionSyndax pharmaceuticalsEuropean commissionSyndax pharmaceuticals incPrnewswire syndax pharmaceuticals nasdaqOncology centerAmerican society of hematologyPharmaceuticals incChief executiveAmerican societyMeeting presentationsOrphan drug designation